Background The coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continues to challenge the health …

Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the …

Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China in mid-December 2019, and declared a pandemic by the …

This meta-analysis was conducted with the aim to assess the safety and efficacy of
favipiravir in treating patients with coronavirus disease 2019 (COVID-19). It was carried out …

Introduction: COVID-19 is a coronavirus-based infectious illness that was first detected at the
end of 2019 in Wuhan, China. The novel virus induces severe acute respiratory syndrome …

Background This meta-analysis of randomized controlled trials (RCTs) investigated the
clinical efficacy and safety of favipiravir for patients with mild-to-critical COVID-19. Methods …

Abstract Context: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) appeared for the first time in December 2019 in …

To the Editor: The COVID-19 pandemic continues to be a global source of concern. Several
therapies have been investigated for COVID-19 including oral antivirals, 1, 2 repurposed …

The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …

Background Favipiravir possesses high utility for treating patients with COVID-19. However,
research examining the efficacy and safety of favipiravir for patients with COVID-19 is …